Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Report Date: May 5, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The company announced its financial results for the quarter ended March 31, 2026. The full details are contained in a press release furnished as Exhibit 99.1 to this filing.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing the press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide specific values for the following metrics:
- Revenue: Not stated in filing text.
- Profit/Loss: Not stated in filing text.
- Cash Flow: Not stated in filing text.
- Margins: Not stated in filing text.
- Debt and Liquidity: Not stated in filing text.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the announcement of Q1 2026 results but does not include specific management commentary, forward-looking guidance, or risk factors within the text of the 8-K itself.
Unusual Items: No unusual items are described in the provided text.
Legal Disclaimer: The information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02.
- Confirm the status of the company as an emerging growth company (indicated as checked in the filing).
- Note the signatory is Jason S. Robins, Interim Chief Financial Officer.